Skip to content
Clinical Trials – home
Not recruitingRare disease

Safety and Tolerability of Repeated 400 mg ARM210 Doses in Healthy Adults for Cardiac Arrhythmias

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study involves healthy adult volunteers and focuses on a rare heart condition called Cardiac arrhythmias, which means the heart beats irregularly. The medication being tested is an oral tablet named ARM210, given at a dose of 400 mg each day for ten days, and it is compared with a placebo tablet that contains lactose but no active drug. The purpose of the study is to assess the safety, tolerability, and pharmacokinetics—how the drug is absorbed, distributed, metabolized, and eliminated—of repeat doses of the test medication.

Participants will be randomly assigned to receive either the study drug or the placebo, taking one tablet each day for ten consecutive days. Throughout the study, volunteers will have regular check‑ups that include blood tests, measurements of vital signs such as blood pressure and heart rate, a physical examination, and a heart test called a 12-lead electrocardiogram, which records the electrical activity of the heart. Any side effects, changes in laboratory results, or abnormalities in the heart test will be recorded to evaluate how well the medication is tolerated.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Visit (Day 0)

    You will attend a first visit after joining the study. During this visit a physical examination, measurement of vital signs (such as blood pressure and heart rate), and a 12‑lead electrocardiogram (ECG, a test that records the electrical activity of the heart) will be performed. Blood and urine samples will be taken for laboratory tests. After these assessments you will be randomly assigned to receive either the investigational drug ARM210 or a placebo tablet containing lactose. You will receive a supply of tablets and written instructions on how to take them.

  2. Step 2

    Daily Dosing (Days 1‑10)

    Each morning you will take one tablet with a glass of water. If you have been assigned to the active group, the tablet contains 400 mg of ARM210. If you have been assigned to the control group, the tablet contains only lactose and has no active medication. The tablets are taken once daily for ten consecutive days. You should keep a simple diary noting the time you took the tablet and any symptoms or side effects you experience.

  3. Step 3

    Mid‑Study Safety Check (Day 5)

    On the fifth day you will return to the clinic for a safety check. The staff will repeat vital signs, perform another ECG, and collect a small blood sample to evaluate laboratory values. You will be asked about any adverse events (any new or worsening symptoms) that occurred since the start of dosing.

  4. Step 4

    End‑of‑Dosing Visit (Day 10)

    On the tenth day, after taking the final tablet, you will attend another clinic visit. The same assessments as on Day 5 will be repeated: vital signs, ECG, and laboratory tests. The staff will also collect the remaining tablets and review your diary to ensure all doses were taken as instructed.

  5. Step 5

    Final Study Visit (Day 11)

    One day after the last dose, you will have a final visit. This visit includes a complete physical examination, vital signs measurement, a final ECG, and final laboratory testing. All study data will be reviewed, and you will receive information about the overall study results when they become available.

Who can join the trial?

11 criteria

  • You must be a man or a woman; women can be of child‑bearing age, not able to have children, or post‑menopausal.
  • You need to be in good physical and mental health, as shown by your medical history, a physical exam, lab tests, an electrocardiogram (ECG) (a test that records the heart’s electrical activity), and normal vital signs, according to the study doctor.
  • You must be willing and able to sign the informed consent form (ICF), which explains the study and your rights.
  • Your age must be between 18 and 55 years at the time of screening.
  • Your body mass index (BMI) (a measure of weight relative to height) must be between 18.0 and 32.0 kg/m² when you are screened.
  • You must weigh at least 50 kilograms (about 110 pounds).
  • You must be a healthy volunteer, not having any illness that would affect the study.
  • If you are male and not surgically sterile, you must not donate sperm from the first day you take the study drug until 90 days after the final follow‑up, and you must use effective contraception (hormonal birth control or an intrauterine device plus a condom, diaphragm, or cervical cap) or choose complete abstinence.
  • If you are female, you must not be pregnant or breastfeeding, and you must use a highly effective birth‑control method (such as hormonal pills, a vaginal ring, a patch, an intrauterine device, a hormone‑releasing system, an implant like Depo‑Provera®, tubal ligation, or complete abstinence) starting at least two weeks before the first dose and continue it, combined with a condom, diaphragm, or cervical cap, until 90 days after the final follow‑up. Alternatively, you may be considered non‑child‑bearing if you are post‑menopausal (no periods for 12 months and a follicle stimulating hormone (FSH) level over 40 mIU/mL), surgically sterile (hysterectomy or removal of both ovaries), or born without a uterus.
  • You must be able and willing to avoid alcohol for at least 48 hours (2 days) before the screening visit and before staying in the clinical research center.
  • You must be able and willing to avoid drinks and foods that contain caffeine (such as coffee, tea, cola, chocolate, energy drinks) and grapefruit or grapefruit juice for at least 48 hours (2 days) before your first stay in the clinical research center.

Who cannot join the trial?

15 criteria

  • Being an employee of ICON or the study sponsor.
  • Using any prescribed medication (medicine given by a doctor) within 14 days before coming to the research center, except for hormonal birth control or a stable thyroid medicine that has been taken for at least 6 months.
  • Using any over‑the‑counter medication (medicine you can buy without a prescription), vitamins, dietary supplements, or herbal medications (like St. John’s wort) within 7 days before coming, except for paracetamol (also called acetaminophen), which is allowed up to admission and as needed during the study.
  • Having taken part in another drug study within 30 days before this study, or having taken part in four or more drug studies in the past 12 months.
  • Donating or losing more than 450 mL of blood (about one pint) within 60 days before the study drug is given.
  • Having a significant and/or acute illness (a serious or sudden sickness) within 5 days before the study drug that could affect safety checks, according to the Investigator.
  • Having veins that are not suitable for blood sampling (drawing blood).
  • Having a history of important drug and/or food allergies.
  • Smoking more than 5 cigarettes, 1 cigar, or 1 pipe each day, or using any tobacco product within 48 hours (2 days) before the first visit.
  • Having a history of alcohol abuse or drug addiction within the past 5 years, including cannabis.
  • Testing positive on a drug and alcohol screen for substances such as opiates, methadone, cocaine, amphetamines (including ecstasy), cannabinoids (marijuana), barbiturates, benzodiazepines, certain antidepressants, or alcohol at screening or admission.
  • Drinking more than 24 units of alcohol per week (one unit is roughly 250 mL of beer, 100 mL of wine, or 35 mL of spirits).
  • Testing positive for hepatitis B surface antigen, hepatitis C antibodies, or HIV 1 and 2 antibodies.
  • Having any condition that could affect the absorption, distribution, metabolism, or excretion (how the body processes) medicines.
  • Having a history of convulsive seizures, head trauma (injury) with loss of consciousness, or other neurological or muscle diseases.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

ARM210 is an experimental oral tablet being studied for its safety and how well people can tolerate it. In this trial, healthy adult volunteers took the tablet once a day for ten days. Researchers are looking at how the drug is processed in the body and checking for any side effects or problems that might occur during the short‑term use.

What is already known about the treatment

  • Oral Tablets containing Lactose

    These are plain tablets made of lactose that are taken by mouth and used only as a control in the study. They do not contain any active drug and therefore have no therapeutic use in medicine. Because they are inert, they are not listed in medical literature as a treatment. Their role is to help compare the effects of the test drug against a neutral substance.

  • ARM210

    ARM210 is an oral tablet taken by mouth, with each dose containing 400 mg of the active ingredient. It is an experimental medication that is still being studied and is not yet approved for clinical use. The drug is being tested for treating irregular heartbeats (cardiac arrhythmias) and works by gently blocking calcium signals in heart cells, which helps the heart beat more regularly. It belongs to the class of calcium‑channel blocker anti‑arrhythmic agents.

Investigated diseases

Cardiac arrhythmias - Cardiac arrhythmias are disturbances in the heart’s rhythm, causing beats that are too fast, too slow, or irregular. They arise when the electrical signals that coordinate heartbeats are disrupted. Some arrhythmias begin intermittently and may become more frequent over time. Others may start as brief episodes and evolve into a persistent pattern. The condition can affect how efficiently the heart pumps blood as the rhythm changes. Progression varies, with some remaining stable while others may advance to involve larger portions of the heart’s conduction system.
Trial detailsLast updated 17 Nov 2026
Age18+ yearsPhasePhase ITrial ID2023-509086-20-00Protocol codeCL1-210-03Estimated enrolment8 patientsSponsorRycarma Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.